Company intelligence / Profile preview
M6P Therapeutics
St. Louis, Missouri, United Statesm6ptherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
The company has presented promising preclinical data for multiple lysosomal storage disorders including Gaucher disease, Pompe disease, and Mucolipidosis type II. They presented data at the 19th Annual WORLD Symposium 2023 and other scientific conferences, showing potential efficacy in their preclinical programs[2][5].
- Therapeutic areas
- Rare DiseasesNeurologyMetabolic Disorders
- Modalities
- Enzyme replacement therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Beyond the preview
Go deeper on M6P Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M6P Therapeutics.